JLK's sales grew 135.2% year-over-year.

JLK (CEO Dongmin Kim) , a medical artificial intelligence (AI) specialized company, announced on the 6th that it recorded a 135.2% sales growth year-on-year through a 30% change in sales disclosure.

This performance is seen as a result of the company's strategy to transition from a traditional solution-centric business structure to a subscription-based AI and platform-based business, which is beginning to show full results.

The company cited the expansion of subscription-based AI solutions, centered on major domestic general hospitals and regional hub hospitals, increased clinical utilization of its stroke AI solution portfolio, and improved revenue recognition due to the shift to a platform-based business structure as key factors in its performance growth.

JLK has built a portfolio of AI solutions spanning the entire process from stroke diagnosis to treatment decision-making. It has moved beyond single-product sales to a subscription model that integrates multiple solutions. This business structure is believed to simultaneously enhance usability and cost-effectiveness in the medical field, while also strengthening its stable recurring revenue base.

The company plans to secure additional growth momentum this year by expanding its overseas operations, focusing on Japan and the United States. In the Japanese market, the company is pursuing a direct sales and partnership strategy centered around its local subsidiary, leveraging its PMDA-approved stroke AI solution. In the US market, the company also plans to expand business opportunities, focusing on major medical institutions and academic societies.

Kim Dong-min, CEO of JLK, said that these results show that the business model transformation is starting to lead to financial performance, and that the company will continue its growth by expanding its overseas business.

Meanwhile, JLK is continuously accumulating domestic and international approvals and clinical verification in the field of stroke AI, and is pursuing a leap forward as an AI platform company that is actually used in medical settings.

• See more related articles